NFL Biosciences
ALNFL | PA
Overview
Corporate Details
- ISIN(s):
- FR0014003XO1 (+1 more)
- LEI:
- 9695006VJWNTN4UNHA27
- Country:
- France
- Address:
- 199 RUE HELENE BOUCHER, 34170 CASTELNAU-LE-LEZ
- Website:
- https://www.nflbiosciences.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of substance addictions. The company's lead product, NFL-101, is a patented, nicotine-free treatment for smoking cessation derived from a protein extract of tobacco leaves. Its pipeline also includes NFL-301, a candidate targeting the reduction of excessive alcohol consumption. NFL Biosciences operates on an R&D-focused model, advancing its drug candidates through preclinical and clinical trials with the strategic goal of licensing them to larger pharmaceutical companies for late-stage development and commercialization.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for NFL Biosciences.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-23 07:30 |
Share Issue/Capital Change
NFL Biosciences announces the success of its capital increase capped at €3 mill…
|
English | 311.5 KB | |
| 2025-05-23 07:30 |
Share Issue/Capital Change
Vif succès de l’augmentation de capital de NFL Biosciences avec une levée plafo…
|
French | 304.2 KB | |
| 2025-05-22 17:45 |
Share Issue/Capital Change
NFL Biosciences launches a capital increase of approximately €2.2 million
|
English | 354.2 KB | |
| 2025-05-22 17:45 |
Share Issue/Capital Change
NFL Biosciences lance une levée de fonds d’environ 2,2 millions d’euros par voi…
|
French | 310.7 KB | |
| 2025-05-21 17:45 |
Post-Annual General Meeting Information
NFL Biosciences : compte rendu de l’assemblée générale mixte du 21 mai 2025
|
French | 151.3 KB | |
| 2025-05-12 08:30 |
Board/Management Information
NFL Biosciences strengthens its scientific committee with world-class experts t…
|
English | 177.7 KB | |
| 2025-05-12 08:30 |
Regulatory News Service
NFL Biosciences renforce son Comité Scientifique avec des experts de renommée m…
|
French | 175.8 KB | |
| 2025-05-06 18:40 |
Report Publication Announcement
Assemblée générale mixte du 21 mai 2025 : modalités de mise à disposition et co…
|
French | 151.8 KB | |
| 2025-05-05 08:30 |
Regulatory News Service
NFL Biosciences announces results from a new study conducted with the CEA provi…
|
English | 352.0 KB | |
| 2025-05-05 08:30 |
Earnings Release
NFL Biosciences annonce les résultats d’une nouvelle étude menée avec le CEA pe…
|
French | 326.4 KB | |
| 2025-04-24 17:45 |
Regulatory News Service
Marex Group initiates coverage of NFL Biosciences with a Buy rating
|
English | 185.7 KB | |
| 2025-04-24 17:45 |
Regulatory News Service
Marex Group initie à l’achat la couverture de NFL Biosciences
|
French | 164.8 KB | |
| 2025-04-15 18:00 |
Report Publication Announcement
NFL Biosciences annonce la mise à disposition de son rapport financier annuel 2…
|
French | 179.3 KB | |
| 2025-04-11 17:45 |
Earnings Release
NFL Biosciences presents its 2024 annual results and provides an update on its…
|
English | 346.5 KB | |
| 2025-04-11 17:45 |
Earnings Release
NFL Biosciences présente ses résultats annuels 2024 et fait le point sur son pr…
|
French | 311.1 KB |
Automate Your Workflow. Get a real-time feed of all NFL Biosciences filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for NFL Biosciences via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
